America’s First Regenexx® Network Provider
Leading Regenerative Orthopedic Treatment Options, Including Platelet-Rich Plasma and Bone Marrow Concentrate Procedures for Orthopedic Injuries, Arthritis and Other Conditions.
Regenexx® Procedures provide non-surgical treatment options for those suffering from pain related to osteoarthritis, joint injuries, spine pain, overuse conditions, and common sports injuries. These medical procedures are only performed by highly-skilled doctors and are used to help reduce pain and improve function. Regenexx procedures have helped thousands of patients improve their quality of life, return to the activities they enjoy, and avoid the need for surgery or joint replacement.
*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.
Regenexx® Procedures – The Trusted Alternative to Surgery
Regenexx Physicians represent a very selective, highly-skilled, interventional orthobiologics network that is 100% focused on orthopedic conditions:
- Spine pain and disorders
- Osteoarthritis of joints and spine
- Tendon and ligament tears
- Cartilage damage
- And many more conditions that cause pain.
A Leader in Regenerative Orthopedic Treatment Options for Arthritis, Joint Injuries and Spine Conditions.
Watch this video for an in-depth overview of how Regenexx treatments and research are designed to produce the best possible outcomes for patients with orthopedic conditions, joint injuries, arthritis, or spine pain.Learn more
More than 140,900 highly specific image-guided Regenexx® Procedures have been performed since Regenexx pioneered the field of interventional orthopedics, using bone marrow concentrate to treat common orthopedic problems in 2005.
The published research on Regenexx procedures accounts for approximately 44% of the world’s research on the use of bone marrow concentrate for orthopedic conditions (cumulative n of patients published & treated with bone marrow concentrate as of 1/1/2019)